The global biotechnology CMO and CDMO sector is estimated at US$82.55 billion in 2026 and is projected to reach US$220.60 billion by 2035, expanding at a CAGR of 11.54% from 2026 to 2035. Rising demand for biologics, biosimilars, vaccines, cell and gene therapies, and RNA-based treatments is increasing the need for specialized development and manufacturing services.
What Are Biotechnology CMO and CDMO Services?
CMOs primarily provide outsourced manufacturing, while CDMOs offer broader support covering process development, optimization, clinical production, analytical testing, regulatory assistance, fill-finish, and commercial manufacturing.
Pharmaceutical and biotechnology companies increasingly use these services to access specialized expertise, advanced facilities, and production capacity without making large investments in their own infrastructure.
Key Growth Drivers
- Rising demand for biologics: Growing use of monoclonal antibodies, recombinant proteins, vaccines, and biosimilars is increasing the need for specialized manufacturing.
- Expansion of cell and gene therapies: Advanced therapies require specialized facilities, technologies, and expertise, creating new opportunities for CDMOs.
- Increasing outsourcing: Biotechnology companies are outsourcing development and manufacturing to reduce costs, shorten timelines, and improve production flexibility.
- Advanced manufacturing technologies: Single-use systems, automation, continuous processing, and modular facilities are improving production efficiency.
- Growth of emerging biotechnology companies: Smaller companies often rely on external manufacturing partners because they have limited internal production capabilities.
AI Is Transforming Biomanufacturing
Artificial intelligence is becoming an important tool across biotechnology development and manufacturing. AI can analyze historical production data, support process optimization, identify potential quality issues, and improve supply-chain management.
Combined with automation and advanced analytics, AI can help CDMOs improve manufacturing consistency, accelerate decision-making, and provide better visibility into development projects.
Key Segment Insights
Commercial manufacturing accounted for approximately 46% in 2025, supported by strong demand for large-scale biologics production.
Monoclonal antibodies led with around 41%, reflecting their extensive use in therapeutic development.
Commercial-scale operations held approximately 53%, while flexible and hybrid manufacturing is expected to grow rapidly as companies seek scalable production options.
Mammalian cell culture represented about 48%, driven by its importance in producing complex biologics.
Regional Outlook
North America led with approximately 42% in 2025, supported by advanced biotechnology infrastructure, strong pharmaceutical activity, and significant outsourcing.
Asia Pacific is expected to experience the fastest growth due to cost-effective manufacturing, skilled talent, expanding biopharmaceutical capabilities, and supportive government initiatives.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/6253
Future Outlook
The biotechnology CMO and CDMO sector is moving toward flexible manufacturing, AI-enabled operations, cell and gene therapy production, mRNA technologies, and advanced biologics manufacturing.
As pharmaceutical and biotechnology companies continue to outsource complex production activities, specialized CMO and CDMO providers will play an increasingly important role in bringing innovative therapies from development to patients.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium